A global pioneer in providing clients with comprehensive packaging solutions for injectable medications said today that its North American business would see substantial growth in 2022, with revenues growing by more than 40% year-over-year. Strong revenue improvements in the company’s international markets paralleled the expansion in North America, reflecting the multimillion-dollar expenditures made by Bormioli to extend its skills as a provider of comprehensive packaging solutions for injectable pharmaceuticals.
Bormioli Pharma, founded in 1825 as the glass container maker Bormioli Rocco, has a long history of innovation in the packaging sector. The firm now offers the pharmaceutical and biopharmaceutical sectors with comprehensive packaging solutions, including glass and plastic bottles, plastic and aluminum closures, and accessories.
As a result of the lingering impacts of the COVID-19 epidemic and the related supply chain disruptions, the U.S. glass bottle industry is facing ongoing supply challenges for injectable glass packaging. Bormioli is devoted to offering a comprehensive solution with its ever developing capabilities in the areas of high-value glass vials, rubber stoppers, and aluminum seals. Particularly, the firm has invested in modern technology for the manufacturing of tubular glass vials, a platform upgrade for molded glass, and an expansion of clean-room capabilities for the manufacture of rubber stoppers. Recent purchases have enabled Bormioli to make rubber and aluminum closures, as well as tubular glass vials, in a dependable and efficient manner.